FRA:NOV - Deutsche Boerse Ag - DK0062498333 - Common Stock - Currency: EUR
FRA:NOV (5/6/2025, 7:00:00 PM)
58.97
-2.32 (-3.79%)
The current stock price of NOV.DE is 58.97 EUR. In the past month the price decreased by -2.93%. In the past year, price decreased by -50.76%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
1LLY.MI | ELI LILLY & CO | 57.79 | 664.54B | ||
LLY.DE | ELI LILLY & CO | 57.77 | 664.26B | ||
ZEG.DE | ASTRAZENECA PLC | 19.35 | 391.11B | ||
JNJ.DE | JOHNSON & JOHNSON | 15.45 | 329.44B | ||
1SAN.MI | SANOFI | 14.56 | 239.91B | ||
SAN.PA | SANOFI | 14.23 | 234.53B | ||
SNW.DE | SANOFI | 14.2 | 234.01B | ||
1MRKX.MI | MERCK & CO. INC. | 10.82 | 186.97B | ||
6MK.DE | MERCK & CO. INC. | 10.35 | 178.92B | ||
PFE.DE | PFIZER INC | 7.33 | 117.71B | ||
1PFE.MI | PFIZER INC | 7.33 | 117.60B | ||
BRM.DE | BRISTOL-MYERS SQUIBB CO | 6.63 | 87.29B |
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
NOVO NORDISK A/S-B
Novo Alle 1
Bagsvaerd DK
Employees: 76826
Phone: 4544448888
The current stock price of NOV.DE is 58.97 EUR. The price decreased by -3.79% in the last trading session.
The exchange symbol of NOVO NORDISK A/S-B is NOV and it is listed on the Deutsche Boerse Ag exchange.
NOV.DE stock is listed on the Deutsche Boerse Ag exchange.
32 analysts have analysed NOV.DE and the average price target is 99.56 EUR. This implies a price increase of 68.84% is expected in the next year compared to the current price of 58.97. Check the NOVO NORDISK A/S-B stock analysts ratings, price target forecast and up-and down grades for more detailed information.
NOVO NORDISK A/S-B (NOV.DE) has a market capitalization of 261.77B EUR. This makes NOV.DE a Mega Cap stock.
NOVO NORDISK A/S-B (NOV.DE) currently has 76826 employees.
NOVO NORDISK A/S-B (NOV.DE) has a resistance level at 60.84. Check the full technical report for a detailed analysis of NOV.DE support and resistance levels.
The Revenue of NOVO NORDISK A/S-B (NOV.DE) is expected to grow by 21.03% in the next year. Check the estimates tab for more information on the NOV.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
NOVO NORDISK A/S-B (NOV.DE) has a dividend yield of 2.57%. The yearly dividend amount is currently 1.33. Check the full fundamental report for a detailed analysis of NOV.DE dividend history, reliability and sustainability.
NOVO NORDISK A/S-B (NOV.DE) will report earnings on 2025-05-07, before the market open.
The PE ratio for NOVO NORDISK A/S-B (NOV.DE) is 19.46. This is based on the reported non-GAAP earnings per share of 3.03 and the current share price of 58.97 EUR. Check the full fundamental report for a full analysis of the valuation metrics for NOV.DE.
ChartMill assigns a fundamental rating of 7 / 10 to NOV.DE. Both the health and profitability get an excellent rating, making NOV.DE a very profitable company, without any liquidiy or solvency issues.
Over the last trailing twelve months NOV.DE reported a non-GAAP Earnings per Share(EPS) of 3.03. The EPS increased by 21.57% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 34.78% | ||
ROA | 21.68% | ||
ROE | 70.38% | ||
Debt/Equity | 0.62 |
ChartMill assigns a Buy % Consensus number of 74% to NOV.DE. The Buy consensus is the average rating of analysts ratings from 32 analysts.
For the next year, analysts expect an EPS growth of 19.72% and a revenue growth 21.03% for NOV.DE